On the afternoon of June 21, leaders and representatives from several renowned investment institutions—including BVCF, Primecare Ventures (约印投资), Tongshang Group, Yongyuan Fund, Chaoqian Investment, and Shanghai Unicorn Technology Empowerment—visited Zhejiang Tianyuan Biotechnology Co., Ltd. for an inspection tour, gaining an in-depth understanding of the company's technological innovation achievements and industrial development layout in the biopharmaceutical field. Huang Bisheng, Chairman of Tianyuan Biotechnology, Jiao Mingming, General Manager, and Chen Junjie, Chief Technology Officer, warmly received the delegation and accompanied them throughout the visit.

      In the company's science and technology exhibition hall, the delegation attentively listened to presentations on the company's development history, core technology system, research platform construction, and industrialization layout. As a technology-driven enterprise focused on the development of innovative iPSC drugs, Tianyuan Biotechnology has consistently adhered to an innovation-driven development strategy and has formed a technology platform with independent intellectual property rights and industrialization potential. The delegation then proceeded to visit the company's laboratories. During the tour, iPS-derived cardiomyocytes being differentiated and cultured in the laboratory were beating rhythmically and spontaneously on their own—the "jumping" cardiomyocytes aroused great interest among the delegation members. The advanced laboratory equipment, standardized R&D system, and continuous innovation achievements gave the delegation a more direct and in-depth understanding of Tianyuan Biotechnology's research capabilities and technological accumulation.

      At the symposium, General Manager Jiao Mingming gave a systematic introduction centered on the company's business plan. He stated that Tianyuan Biotechnology, with its independently developed iPSC technology at its core, is actively expanding into the fields of cell therapy and regenerative medicine, while proactively exploring the deep integration of emerging technologies such as AI artificial intelligence with life sciences, building development momentum for future intelligent biopharmaceutical R&D.

      Chairman Huang Bisheng, drawing on industry development trends and the company's strategic planning, provided a detailed introduction to Tianyuan Biotechnology's development advantages and future layout. He stated that the company possesses a high-level scientific research team, a well-established R&D platform, and continuously accumulating technological achievements, and has established close cooperative relationships with multiple universities and research institutes. Going forward, the company will continue to increase investment in scientific research, deepen collaborative industry-academia-research innovation, accelerate the translation and industrialization of research achievements, and continuously enhance its core competitiveness, injecting new momentum into the high-quality development of the life and health industry.

      Chief Technology Officer Chen Junjie then shared the company's technological R&D and innovation achievements, focusing on core technology advances such as iPS-derived cardiomyocytes and organoid research. He stated that Tianyuan Biotechnology has always adhered to technology innovation as its guide, continuously breaking through key technical bottlenecks and advancing cell technology toward standardization, scale-up, and industrialization, laying a solid foundation for future innovative drug development and precision medicine applications.

      During the interactive exchange session, the attending investment institutions gained an in-depth understanding of the company's clinical cooperation layout, intellectual property protection system, and core technological competitive advantages. Tianyuan Biotechnology introduced its clinical cooperation network, intellectual property portfolio, and core technologies such as iPS-derived cardiomyocyte progenitor cells. Representatives of the investment institutions fully affirmed the company's solid technological accumulation, well-established innovation system, and clear path toward industrialization, and expressed strong recognition and expectations for the development prospects of cell therapy and regenerative medicine, as well as the company's future growth potential.

      This inspection and exchange not only further enhanced the capital market's understanding and awareness of Tianyuan Biotechnology, but also built a valuable bridge of communication for the company to deepen industrial cooperation, connect quality resources, and accelerate the translation of innovative achievements in the future. Standing at a new starting point of the booming bio-economy, Tianyuan Biotechnology will continue to uphold its corporate mission of "Gathering the Essence of Science, Safeguarding Human Health," driven by technological innovation and guided by industrial transformation, continuously exploring the infinite possibilities of life science, and contributing more "Tianyuan strength" to the high-quality development of China's biopharmaceutical industry.

      Founded in 2017, Zhejiang Tianyuan Biotechnology Co., Ltd. is a platform-based biopharmaceutical enterprise driven by AI + iPSC technology and dedicated to developing drugs for heart failure treatment. With its iPS seed cell bank, tumor cell bank, and HLA compatibility matching system as cornerstones, the company has built a full-chain R&D platform covering cell reprogramming, disease model construction, and candidate drug validation. Leveraging the policy advantages of Hainan's "Medical Special Zone," the company has opened up the "last mile" of clinical translation; through its regional network of facilities, it has achieved integrated operations spanning collection, preparation, R&D, and application; and with a closed-loop marketing ecosystem, it connects medical institutions, research platforms, and end users.